Varje dag samlar vi de senast publicerade vetenskapliga studierna om hampa, CBD och cannabis och sammanfattar kort vad var och en undersökte — på svenska och engelska. Alla länkar går till primärkällan (PubMed, Europe PMC eller ClinicalTrials.gov). Sammanfattningarna är neutrala beskrivningar av vad forskarna studerade, inte hälsopåståenden.
Haplotype-resolved regulation of secondary metabolism in cannabis.
Hortic Res · 2026 Sep · PubMed
Svenska: Cannabis sativa produces a rich array of specialized metabolites, including cannabinoids, terpenoids, and flavonoids, which are of immense therapeutic interest.
Effects of delta-9 tetrahydrocannabinol and cannabidiol on cognitive outcomes following acute use of cannabis for chronic pain.
Psychopharmacology (Berl) · 2026 Sep 1 · PubMed
Svenska: An estimated two-thirds of medical cannabis users in the United States are motivated by chronic pain, but clinical guidance remains guarded as to whether the potential benefit of cannabinoids for pain outweighs potential risks, such as effects on cognition.
Cannabidiol and neural correlates of threat anticipation in alcohol use disorder.
Psychopharmacology (Berl) · 2026 Sep 1 · PubMed
Svenska: Cannabidiol (CBD) has previously been suggested to be an emerging pharmacotherapy for Alcohol Use Disorder (AUD), however, results from clinical studies remain mixed and potential mechanisms remain elusive.
Targeted phytocannabinomics provides new insights into the biosynthetic origin of cis-Δ⁹-THCA in Cannabis sativa L.
J Pharm Biomed Anal · 2026 Sep 1 · PubMed
Svenska: Recent studies have reported the occurrence of cis-Δ⁹-tetrahydrocannabinol (cis-Δ⁹-THC) and its carboxylated precursor, cis-Δ⁹-tetrahydrocannabinolic acid (cis-Δ⁹-THCA), minor isomers of the well-known trans counterparts.
Development of a Lifestyle Physical Activity Intervention to Reduce Risk for Perinatal Cannabis Use - RCT
ClinicalTrials.gov (ACTIVE_NOT_RECRUITING) · 2026-08-28 · ClinicalTrials.gov
Svenska: The overall goal of this pilot study is to develop and preliminarily evaluate an LPA intervention designed to reduce cannabis use during pregnancy.
Stratification and Treatment in Early Psychosis Study - ENHANCE
ClinicalTrials.gov (RECRUITING) · 2026-08-31 · ClinicalTrials.gov
Svenska: The purpose of this study is: * To investigate whether the response to antipsychotic treatment can be enhanced by adding cannabidiol (CBD) to the existing treatment, compared to placebo, in participants with a first episode of psychosis, who have had a suboptimal or no response to their first antips.
Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome
ClinicalTrials.gov (COMPLETED) · 2026-09-01 · ClinicalTrials.gov
Svenska: This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of cannabidiol administered as ZYN002 for the treatment of children, adolescent, and young adult patients with Fragile X syndrome (FXS).
Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
ClinicalTrials.gov (ACTIVE_NOT_RECRUITING) · 2026-09-01 · ClinicalTrials.gov
Svenska: The prevalence of daily cannabis use and Cannabis Use Disorder (CUD) has increased in the United States over the past two decades. Brief, computerized harm reduction interventions that target specific high-risk CUD populations could be an efficient approach to reducing CUD.